The Albany Gazette - enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

NYSE - LSE

SCS	0.12%	16.14	$
CMSD	-0.65%	23.25	$
CMSC	-0.56%	23.3	$
BTI	-2.22%	57.1	$
GSK	-0.14%	48.81	$
BCC	0.33%	76.51	$
NGG	0.32%	74.93	$
BCE	1.31%	23.71	$
RIO	-1.43%	75.66	$
BP	-0.77%	35.26	$
AZN	-0.51%	89.83	$
RYCEF	-1.71%	14.6	$
JRI	-0.15%	13.7	$
VOD	0.4%	12.59	$
RELX	0.25%	40.38	$
RBGPF	0%	81.17	$

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

TECHNOLOGY 16.04.2025

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

Moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Tuesday, April 22^nd at 4:00 PM ET

Text size:

IRVINE, CA / ACCESS Newswire / April 16, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in the Virtual Investor Closing Bell Series on Tuesday, April 22, 2025 at 4:00 PM ET.

As part of the event, Mr. Berman will provide a corporate overview and discuss the Company's portfolio of novel implantable replacement venous valve technologies, the VenoValve® and enVVe®, for the treatment of severe deep venous CVI. In addition to the moderated discussion, there will be a live question and answer session. Mr. Berman will answer as many questions as possible in the time allowed.

A live video webcast of the presentation will be available on the Events page of the Company's website (www.envveno.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.

About enVVeno Medical Corporation

enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe.

INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
[email protected]
(908) 824-0775

MEDIA CONTACT:
Glenn Silver, FINN Partners
[email protected]
(973) 818-8198

SOURCE: enVVeno Medical Corporation

View the original press release on ACCESS Newswire

(P.Clark--TAG)

Featured

Why SpaceX IPO plan is generating so much buzz

More than 20 years after founding SpaceX, the record-breaking company that transformed the global space industry, Elon Musk is planning to take the enterprise public.

Spain opens doors to descendants of Franco-era exiles

Spain has received a surge of citizenship applications from descendants of emigrants who fled the country's 1930s civil war and Francisco Franco's dictatorship under a scheme aimed at addressing historical injustices.

Laughing about science more important than ever: Ig Nobel founder

With science increasingly coming under attack, using humour as a way to get people interested in scientific research is more important than ever, the founder of the satirical Ig Nobel prizes said.

Consensus Mining & Seigniorage Corporation Announces Date of Annual Meeting and Related Deadlines

NEW YORK, NY / ACCESS Newswire / December 12, 2025 / Consensus Mining & Seigniorage Corporation (the "Company") today announced that its 2026 annual meeting of stockholders (the "Annual Meeting") will be held on Wednesday, March 18, 2026. Stockholders of record as of the close of business on January 23, 2026 will be entitled to notice of and to vote at the Annual Meeting or any adjournment or postponement thereof. Pursuant to Section 1.16(b) of the Company's Bylaws, the advance notice deadline for stockholder nominations or other business to be properly brought before the Annual Meeting is December 22, 2025.